New clinical trial combines LMB-100 with nab-paclitaxel for metastatic or locally advanced pancreatic cancer
LMB-100 is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin.
Christine Alewine, Lasker Scholar, in the Laboratory of Molecular Biology is conducting a clinical study for patients with pancreatic cancer using a new immunotoxin drug, called LMB-100. It is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin that is made by most pancreatic cancers. The trial is intended to see how LMB-100 and the chemotherapy drug Nab-Paclitaxel effect pancreatic tumors. Adults age 18 and older with advanced pancreatic cancer can contact Yvonne Mallory, R.N., at (301) 402-0255 to discuss eligibility. https://clinicaltrials.gov/ct2/show/NCT02810418Summary Posted: 07/2016